Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Low-dose tamoxifen for early breast cancer by menopausal status

Andrea De Censi • 29 May 2026
ASCO 2026
Breast Cancer Tamoxifen

Andrea De Censi, MD, Champalimaud Centre, Lisbon, Portugal, explores the efficacy and tolerability of low-dose tamoxifen in reducing breast cancer events following ductal carcinoma in situ (DCIS), atypical ductal hyperplasia (ADH), lobular carcinoma in situ (LCIS), and microinvasive disease. A pooled analysis found menopausal status significantly modified outcomes, with ipsilateral risk reduction predominating in postmenopausal women and contralateral breast cancer prevention in premenopausal women. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrea De Censi

Recommendations for low-dose tamoxifen in pre- and postmenopausal women with breast cancer
0:55
Recommendations for low-dose tamoxifen in pre- and postmenopausal women with breast cancer
Andrea De Censi • 29 May 2026
Low-dose tamoxifen could prevent breast cancer in at-risk young premenopausal women
0:45
Low-dose tamoxifen could prevent breast cancer in at-risk young premenopausal women
Andrea De Censi • 29 May 2026
Low-dose tamoxifen for the treatment of high-risk breast cancer
0:59
Low-dose tamoxifen for the treatment of high-risk breast cancer
Andrea De Censi • 6 Dec 2022
10-year results of a Phase III trial of low-dose tamoxifen in non-invasive breast cancer
1:32
10-year results of a Phase III trial of low-dose tamoxifen in non-invasive breast cancer
Andrea De Censi • 6 Dec 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals